Bicycle Therapeutics touts peptide study

By staff writers

February 15, 2019 -- Bicycle Therapeutics is riding high on the findings of a study published in the February 15 issue of Cancer Research. Results suggest the company's proprietary bicyclic peptide platform is a potentially valuable therapeutic tool for molecular imaging and diagnostics.

The fully synthetic short peptides, known as Bicycles, could become effective agents for molecular imaging to help choose the most appropriate targeted therapy and to monitor patients' responses to treatment, according to the company. The research was conducted in collaboration with the German Cancer Research Center (DKFZ).

The firm is developing Bicycles for the treatment of cancer, as well as in collaboration with others for therapeutic areas that could include respiratory, cardiovascular, hematology, and infectious diseases.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking